Novocure Ltd Stock
€20.24
Your prediction
Novocure Ltd Stock
Pros and Cons of Novocure Ltd in the next few years
Pros
Cons
Performance of Novocure Ltd vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Novocure Ltd | -0.830% | 32.158% | 78.326% | -72.485% | 41.786% | -86.061% | - |
Ironwood Pharmaceuticals | -2.520% | -7.200% | -21.088% | -39.896% | -43.137% | -41.117% | - |
Iovance Biotherapeutics Inc. | -1.210% | -7.525% | -11.439% | 38.319% | 20.569% | -29.851% | - |
Fibrogen Inc. | -0.050% | 5.964% | 6.654% | -92.969% | 33.256% | -93.207% | - |
News
Novocure Reports First Quarter 2024 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of